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ttp://dx.doi.org/10.1016/j.jmoldx.2014.08.006Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) are aggressive tumors of mature B
cells that are distinguished by a combination of histomorphological, phenotypic, and genetic features.
A subset of B-cell lymphomas, however, has one or more characteristics that overlap BL and DLBCL, and
are categorized as B-cell lymphoma unclassiﬁable, with features intermediate between BL and DLBCL
(BCL-U). Molecular analyses support the concept that there is a biological continuum between BL and
DLBCL that includes variable activity of MYC, an oncoprotein once thought to be only associated with
BL, but now recognized as a major predictor of survival among patients with DLBCL treated with R-CHOP
(rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). We tested whether a targeted
expression proﬁling panel could be used to categorize tumors as BL and DLBCL, resolve the molecular
heterogeneity of BCL-U, and capture MYC activity using RNA from formalin-ﬁxed, parafﬁn-embedded
biopsy specimens. A diagnostic molecular classiﬁer accurately predicted pathological diagnoses of BL
and DLBCL, and provided more objective subclassiﬁcation for a subset of BCL-U and genetic double-hit
lymphomas as molecular BL or DLBCL. A molecular classiﬁer of MYC activity correlated with MYC IHC and
stratiﬁed patients with primary DLBCL treated with R-CHOP into high- and low-risk groups. These results
establish a framework for classifying and stratifying MYC-driven, aggressive, B-cell lymphomas on the
basis of quantitative molecular proﬁling that is applicable to ﬁxed biopsy specimens. (J Mol Diagn
2015, 17: 19e30; http://dx.doi.org/10.1016/j.jmoldx.2014.08.006)Supported, in part, by the Leukemia and Lymphoma Society Trans-
lational Research Award, NIH grant P01CA092625 (M.A.S.), Leukemia
and Lymphoma Society grant 6446-13 (S.M.), a Bright Red grant (C.D.C.),
and a Clinical Research Training Fellowship (reference number 13015)
funded by Leukaemia and Lymphoma Research (UK) (C.D.C.).
Disclosures: None declared.The World Health Organization classiﬁcation of tumors
deﬁnes neoplastic diseases according to unique clinical and
biological characteristics.1 Burkitt lymphoma (BL) and
diffuse large B-cell lymphoma (DLBCL) are aggressive
tumors of mature B cells categorized as individual tumorstigative Pathology
.
Carey et altypes. The reliable differentiation of BL from DLBCL is
important, because these tumors are treated with distinct
chemotherapeutic regimens.2,3
BL is a neoplasm composed ofmonomorphic, intermediate-
sized lymphocytes that are positive for markers of mature,
germinal-center B cells and negative for the anti-apoptotic
protein BCL2. Most cells (>95%) are positive for the prolif-
eration marker, Ki-67/MIB1. The genetic hallmark of BL is a
balanced translocation involving theMYC oncogene and, most
commonly, the immunoglobulin heavy chain locus (IGH ).1,4
Mutations in TCF3 and ID3 are also common.5,6 In contrast,
DLBCL is composed of pleomorphic, large lymphoid cells
and, in general, less apoptosis and a lower proliferation index
than BL. DLBCLs express markers of mature B cells, with or
without evidence of germinal center cell derivation, and often
express BCL2. Genetically, only a small subset of DLBCLs
have a MYC translocation, and mutations in TCF3 or ID3 are
rare. However, mutations in genes encoding the components
of the NF-kB and B-cell receptor signaling pathways are
common.1,7e11
Most cases of BL and DLBCL are diagnosed with high
conﬁdence using traditional histopathological, immunophe-
notypic, and targeted genetic analyses. However, it is not
uncommon to encounter tumors with one or more features
overlapping BL and DLBCL. The 2008 World Health
Organization Classiﬁcation of Lymphoid Tumors recognized
these cases with the novel diagnostic category, B-cell lym-
phoma unclassiﬁable, with features intermediate between
DLBCL and BL (BCL-U).1 BCL-U is, by deﬁnition, a het-
erogeneous group, and its diagnosis requires that pathologists
make subtle distinctions in histomorphological features,
immunophenotype, and genetics that may not be highly
reproducible.
Molecular classiﬁcation of aggressive B-cell lymphomas
using comprehensive gene-expression proﬁles (GEPs) of
RNA isolated from frozen tumor samples accurately differ-
entiates BL from DLBCL and conﬁrms that a subset of cases
has transcriptional signatures intermediate between BL and
DLBCL.12,13 However, the pathological diagnoses corre-
sponding to these biologically intermediate tumors have been
inconsistent.13
Complicating the evaluation of aggressive lymphomas is
the recognition that high MYC expression and biological
activity, once thought to be only associated with BL, are
major, independent predictors of poor clinical outcome
among patients with primary DLBCL treated with R-CHOP
(rituximab, cyclophosphamide, doxorubicin, vincristine, and
prednisone).14e18 In some series, the prognostic value of
MYC is enhanced among tumors that co-express
BCL2.14,19e21 Indeed, recent evidence suggests that high
co-expression of MYC and BCL2 in tumor cells provides a
biological basis for the inferior outcome among patients with
the activated B-cell (ABC) type DLBCL when treated with
standard chemotherapy.21
DLBCL with high MYC activity cannot be identiﬁed with
certainty by morphological or genetic studies alone.15 The20detection of MYC in ﬁxed tumor biopsy specimens by
immunohistochemistry (IHC) has the potential to identify
DLBCLs with high MYC protein that corresponds to high
MYC biological activity.15 However, IHC methods are difﬁ-
cult to standardize between institutions, and the interpretation
of IHC staining is subjective.22
These data highlight a need for quantitative methods that
capture the phenotypic, genetic, and molecular heterogeneity of
aggressive B-cell lymphomas in clinical practice. Molecular
classiﬁcation on the basis of the unique GEPs of BL, DLBCL,
and MYC-driven B-cell lymphomas has the potential to satisfy
this need, but, until recently, GEP has not been amenable to
formalin-ﬁxed, parafﬁn-embedded (FFPE) tissues.23e26 Here-
in, we report a method of targeted expression proﬁling, fol-
lowed by a two-stage molecular classiﬁer of aggressive mature
B-cell lymphomas that is applicable to FFPE biopsy specimens.
Materials and Methods
Tumor and Patient Cohorts
This study was performed with approval from the Institu-
tional Review Boards (IRBs) of Brigham and Women’s
Hospital (Boston, MA; IRB number 2010P002736) and
Massachusetts General Hospital (Boston, MA; IRB number
2007P001458). For each case, one or both of the corre-
sponding pathologists of this study (S.J.R. and A.R.S.)
reviewed H&E-stained slides and the original diagnostic
reports to ensure that the ﬁnal diagnosis fulﬁlled 2008 World
Health Organization diagnostic criteria.
The training set (n Z 41) comprises 12 BLs and 29
DLBCLs (one additional DLBCL later failed analytical
quality control). The BLs were selected on the basis of the
quality of available tissue and include all BL subtypes, as
well as pediatric and adult patients (median age of diagnosis,
30.5 years; range, 3 to 62 years) (Supplemental Table S1).
The DLBCLs were selected from a previously published
larger series of adult patients15 who had all been diagnosed as
having DLBCL not otherwise speciﬁed. Previously, MYC
IHC-High was deﬁned as >50% expression in tumor cells,
and MYC IHC-Low was deﬁned as 50% expression in
tumor cells.15 For training, cases were deliberately selected to
represent the extremes of MYC IHC-High (median, 70%;
nZ 13) and MYC IHC-Low (median, 20% to 30%; nZ 16)
to assist development of the MYC activity classiﬁer.
DLBCLs were not selected with regard to cell of origin
(COO27) subtype, but previously classiﬁed using GEP as 10
ABC-type (34.5%), 13 germinal center B-cell type (GBC;
44.8%), 5 type 3 (17.2%), and 1 unclassiﬁed (3.4%)
(Supplemental Table S2).
The test set (nZ 55) comprised 9 BLs (all adult patients, 8
sporadic and 1 immunodeﬁciency associated), 41 DLBCLs,
and 5 BCL-Us (Supplemental Tables S1, S2, and S3). Four
additional cases failed analytical quality control. Eight of
these tumors were genetic double-hit lymphomas (DHLs),
for the purposes of this study deﬁned as the combination of ajmd.amjpathol.org - The Journal of Molecular Diagnostics
Proﬁling of Aggressive B-Cell LymphomasMYC rearrangement and either a BCL2 or BCL6 rearrange-
ment, and these were divided into three tumors with a path-
ological diagnosis of DLBCL and ﬁve tumors with a
pathological diagnosis of BCL-U (Supplemental Table S3).
The DLBCLs included these three DHLs, which were char-
acterized by a combination of MYC and BCL2 rearrange-
ments, as well as one single-hit lymphoma (SHL),
characterized by a MYC rearrangement in isolation. The
DLBCLs were chosen on the basis of the quality of available
biopsy material and to represent a full range of MYC IHC
expression. DLBCLs for the test set were not selected on the
basis of COO subtype.27 COO classiﬁcation data, using GEP
(if available) and/or Han’s IHC criteria,28,29 showed a dis-
tribution of 16 ABC/non-GCB types (39%), 17 GCB-types
(41.5%), 3 type 3 (7.3%), and 5 unclassiﬁed (12.2%)
(Supplemental Table S2). The ﬁve BCL-Us were selected on
the basis of available cases and were all DHLs. Four of the
ﬁve BCL-Us were characterized by a combination of MYC
and BCL2 rearrangements and the remaining case had con-
current MYC and BCL6 rearrangements.
Patients included in an outcome cohort (outcome series;
nZ 40, 22 patients from the training set and 18 from the test
set) were derived from a single institution (Brigham and
Women’s Hospital). All had conﬁrmed primary DLBCLs
and received standard immunochemotherapy (R-CHOP), as
previously reported.15 All clinical data were collected before,
and independent of, the reference and index tests reported in
this study.
IHC and Cytogenetic Analysis
MYC IHC was performed on 96 tumors using a rabbit
monoclonal antibody (clone Y69, catalog number ab32072;
Epitomics/Abcam, Burlingame, CA), as described.15 The
status of the MYC locus was determined by ﬂuorescence in
situ hybridization analysis for 96 tumors using a Vysis LSI
MYC break-apart probe set (catalog number 05-J91-001), as
described.15 Fluorescence in situ hybridization analyses were
performed on indicated cases using the BCL2-IgH dual-
fusion (catalog number 05-J71-001) and BCL6-IgH break-
apart (catalog number 01N23-020; Abbott Laboratories,
Abbott Park, IL) probe sets, respectively, following manu-
facturer’s recommendations. For a few cases, a karyotype
was obtained as part of the original diagnostic evaluation.15
RNA Extraction and Proﬁling
FFPE tissue blocks were divided into sections immediately
before the RNA extraction. For each block, the initial sec-
tion (10 mm thick) was discarded and three subsequent
sections (10 mm thick) were taken for analysis. If the esti-
mated surface area of lesional tissue was <5 mm2, an extra
section (10 mm thick) was taken. Total RNA was isolated
using the Qiagen RNeasy kit (catalog number 73504; Qia-
gen, Hilden, Germany) and quantiﬁed using a Nanodrop
spectrophotometer (NanoDrop Products, Thermo Scientiﬁc,The Journal of Molecular Diagnostics - jmd.amjpathol.orgWilmington, DE). RNA was diluted to 150 to 200 ng/5 mL,
aliquoted, and stored at 80C until use.
For the multiplexed, digital gene expression analysis, 150
to 200 ng of RNA for each sample was hybridized with 20
mL of reporter probes/reaction buffer and 5 mL of capture
probes at 65C for 20 hours. The hybridized samples were
then processed on the NanoString nCounter preparation
station for 2.5 hours and expression data were subsequently
generated on the NanoString nCounter digital analyzer
(NanoString Technologies, Seattle, WA) using the 600
ﬁelds of view setting over 4 hours.30 In total, tumors from
96 patients were proﬁled, with a further 5 tumors (5%)
failing analytical quality control.
Target Selection for the Initial and Final Proﬁling
Panels
Candidate gene targets were initially selected from published
GEPs of BL and DLBCL,12,13 with preference given to genes
within the transcription factor 3 (TCF3)/inhibitor of DNA
binding 3 (ID3) signaling pathway,5 published MYC
targets,31e37 and GEPs of frozen tissue corresponding to
DLBCL samples in the training set.38 These were supple-
mented by additional targets of interest, including house-
keeping (HK) genes (Supplemental Figure S1).
The initial panel of 200 probes included 37 unique tran-
scripts distilled from a previously published TCF3 signature.5
These were subsequently validated by in silico differential
analysis (DA) as best distinguishing BL from DLBCL in two
independent series of B-cell non-Hodgkin lymphomas12,13
(Supplemental Figure S1). The panel also included tran-
scripts from seven published data sets of MYC targets (101
targets selected)31e37 that were validated [false-discovery rate
(FDR), <0.25; fold change, >1.3] by DA against Affymetrix
U133 microarray GEPs of frozen DLBCLs. There were cor-
respondingMYC IHC scores frommatched FFPE tissue in the
training cohort15,38 and differentially expressed genes, sug-
gested by DA, of the GEPs of frozen DLBCLs, with corre-
spondingMYC IHC scores (FDR,<0.25; fold change,>2.0).
Finally, they were supplemented with BCL2 and related
family members (5 targets), housekeeping control transcripts
(15 targets), and select markers of speciﬁc cell lineages (CD3e,
CD68, CD19, CD79a, and CD20) (Supplemental Table S4).
Theﬁnal proﬁling panel, targeting 80 transcripts, was derived
by analyzing data from the training set, both ranking the
importanceof each includedgene andestimatinghow to exclude
many without compromising the predicted accuracy
(Supplemental Table S5). The predicted accuracy of each clas-
siﬁer was assessed on the training set using leave-one-out cross
validation (LOO-CV), aswell as on an independent test data set.
HK Gene Transcripts
Six HK genes were selected on the basis of the following
criteria: i) low variation across samples; ii) even coverage
along the expression range; iii) exclusion of the most21
Carey et alhighly expressed HK genes, because at high levels, the
variation level of the HK genes is comparable to the vari-
ation of the other genes; and iv) exclusion of genes within
regions of known recurrent copy number alteration in
lymphoma.38 On the basis of these criteria, we selected the
following six gene targets: AAMP, HMBS, KARS, PSMB3,
TUBB, and H3F3A.
Data Normalization
Data from the preliminary targeted proﬁling panel (200
genes) and the ﬁnal proﬁling panel (80 genes) were cross
normalized using expression data from six cases tested
with both panels. Normalization of the NanoString data
was performed using the R package NanoStringNorm
(http://cran.rproject.org/web/packages/NanoStringNorm; last
accessed August 21, 2014). We used the sum of the
expression values to estimate the technical assay variation,
the mean to estimate background count levels, and the sum
of the six HK genes to normalize for the RNA sample
content. In addition, the data were log2 transformed.
Unsupervised Clustering of the Normalized Training
Data Set
Unsupervised clustering of the data derived from the training
set was performed using Gene-e (Broad Institute, http://www.
broadinstitute.org/cancer/software/GENE-E, last accessed
August 21, 2014) (Supplemental Table S6). These data were
normalized using Nanostring’s nSolver software packageFigure 1 Target gene selection and the generation of molecular classiﬁers. A
in the initial and ﬁnal proﬁling panels. B: Schematic outlining the protocols for
with the pathological diagnosis of diffuse large B-cell lymphoma (DLBCL) and B-
Diagnostic classiﬁer, and 61 genes were used for the MYC activity classiﬁer. In a
housekeeping genes (HK).
22(version 1.1; NanoString) and then transformed to Log2 using
Gene-e before one minus Pearson hierarchical clustering.
Classiﬁcation Models
Classiﬁcation models were selected on the basis of the training
cohort using a bootstrapping scheme, in which 75% of the
samples were drawn to train a classiﬁcation model, which was
then tested on the remaining 25% of the samples, with the
train/test split repeated 100 times. Elastic nets,39 linear and
polynomial support vector machines, shrunken centroids,40
and a random forest algorithm41 were evaluated as candidate
prediction models. An elastic net39 prediction model was
selected for both classiﬁers, on the basis of a bootstrapping
evaluation scheme on the training set. For the development of
the diagnostic classiﬁer, cases with a pathological diagnosis of
BL and DLBCL were used. For the MYC activity classiﬁer,
onlyDLBCLswere used, excluding BLs. DLBCLswithMYC
IHC>50% and50%were classiﬁed asMYC IHC-High and
IHC-Low, respectively, and these labels were used in the
training of the MYC activity classiﬁer.15
Features were selected on the basis of differential expres-
sion, and their number was determined on the basis of LOO-
CV performed on the training cohort; on the basis of this
procedure, 21 genes were used for the diagnostic classiﬁer and
61 for the MYC classiﬁer (Supplemental Table S7). On the
basis of their performance on the training data set, we selected
the elastic net with an a parameter of 0.1 and a l parameter of
0.1 as the classiﬁer of choice for both stages. Classiﬁcation
accuracy of the ﬁnal elastic net models was assessed on the: Schematic showing the distribution of gene transcripts that were assayed
the molecular classiﬁcation of all aggressive B-cell lymphomas and cases
cell lymphoma unclassiﬁable (BCL-U). Twenty-one genes were used for the
ddition, eight genes were common to both classiﬁers, and there were six
jmd.amjpathol.org - The Journal of Molecular Diagnostics
Proﬁling of Aggressive B-Cell Lymphomastraining cohort using LOO-CV and comparing the predictions
with the outcome of the IHC staining. Unbiased validationwas
then performed by training elastic net models on the entire
training data set and applying them to the classiﬁcation of
cases in the test cohort.
Diagnostic and MYC Activity Scores
Elastic net models output class probabilities between 0 and 1
for each class (probability of class BL in the diagnostic
classiﬁer, and of class MYC IHC-High in the MYC tran-
scriptional activity classiﬁer), reﬂecting the conﬁdence of a
sample prediction. Before analysis, and to reﬂect the concept
of a biological intermediate between BL and DLBCL, we
deﬁned diagnostic scores of>0.75 as representing molecular
BL (mBL), <0.25 as representing molecular DLBCL
(mDLBCL), and 0.25 to 0.75 as representing molecularly
intermediate. MYC activity scores of 1 and 0 corresponded to
tumors with high MYC and low MYC (as modeled on IHC
expression15) with greatest probability, respectively. During
development of the MYC activity classiﬁer, 0.5 was opti-
mized as the cutoff with the highest estimated accuracy to
classify tumors with high and low MYC activity. Therefore,
0.5 is used for statistics regarding the efﬁcacy of the classiﬁer
and for correlation to clinical outcome.
Reproducibility of the Assay
The test set and outcome series were proﬁled using two
builds (independently constructed probe sets) of the 80-geneFigure 2 Unsupervised clustering of the normalized transcript values from 42
initial proﬁling panel (one case later failed quality control during classiﬁcation). T
genes comprising the initial proﬁling panel (heatmap) are shown (15 housekeep
The Journal of Molecular Diagnostics - jmd.amjpathol.orgproﬁling panel. The binding efﬁciency of probes varies be-
tween builds and, therefore, the ﬁnal data set was compiled
by normalizing to both housekeepers and then between
builds, using the expression proﬁles of tumor RNA that were
proﬁled on both. RNA from a subset of cases was proﬁled
multiple times over the course of the study to determine the
reproducibility of the assay (Supplemental Figure S2).
Results
RNA was isolated from FFPE tissue corresponding to 41
aggressive B-cell lymphomas (training set) and was pro-
ﬁled using an initial panel of probes targeting 200 unique
transcripts (Figure 1 and Supplemental Table S4). The
resulting data were used to derive a pair of molecular
classiﬁers, ﬁrst to distinguish BL from DLBCL and sec-
ond to distinguish high and low MYC activity in DLBCL
using a parsimonious, 80-gene signature (Figure 1 and
Supplemental Tables S5 and S7).
Unsupervised Clustering of Targeted Expression
Proﬁles of Select Lymphomas
Unsupervised clustering of the normalized expression data
from the 200-gene signature segregated the training set
tumors into distinct groups that showed a close correlation
with the original pathological diagnoses of BL, DLBCL
MYC IHC-High, and DLBCL MYC IHC-Low (Figure 2).
One DLBCL later failed classiﬁcation quality control andtumors comprising the training cohort and including all target probes in the
he original pathological diagnosis and relative gene expression for the 185
ing genes were excluded). Max, maximum; min, minimum.
23
Carey et alwas not used in subsequent analysis. One case, diagnosed
as BL, clustered with DLBCL MYC IHC-High cases.
Central review of this case conﬁrmed that the tumor was
originally diagnosed correctly. These data support the in
silico methods used to develop the initial proﬁling panel
and demonstrate the technical feasibility of the approach
to broadly group aggressive lymphomas into clinically
relevant categories.
Performance of the Diagnostic Molecular Classiﬁer on
the Training and Test Sets
We tested the diagnostic molecular classiﬁer against data
derived from the training set in a LOO-CV (Figure 3A).
When ranked by the diagnostic classiﬁer scores, these data
largely recapitulated the results obtained from the original
unsupervised clustering analysis using the 200-gene panel.
Of 41 cases, 35 (85%) were classiﬁed as mBL or mDLBCL
with high conﬁdence and correctly matched the patholog-
ical diagnoses of BL or DLBCL, respectively (Figure 3A
and Table 1). Six cases had diagnostic scores of >0.25 and
<0.75 and, thus, were not assigned to the categories of
mBL or mDLBCL, respectively. Nevertheless, three of the
molecularly intermediate cases had a pathological diag-
nosis of BL, and two of these had a diagnostic score >0.5;
three molecularly intermediate cases had a pathological
diagnosis of DLBCL, and two had a diagnostic score<0.5.
We conclude that, in our training cohort, a 21-gene clas-
siﬁer can be used to distinguish most (85%) of pathological
BL from DLBCL.Figure 3 A: Leave-one-out cross-validation of the ﬁnal proﬁling panel and dia
large B-cell lymphoma (DLBCL). B: Results of the diagnostic classiﬁer for the t
categorized according to the original pathological diagnosis, the assigned molecu
intermediate), diagnostic score (line graph, intermediate values shaded), the relat
contribution of each to the classiﬁer (horizontal shaded bar graphs), and MYC-rearr
and additional gene rearrangements are indicated by arrowheads (BCL2-) or a circ
by an asterisk. Max, maximum; min, minimum.
24We next proﬁled and classiﬁed a test set of 55 cases that
included 9 BLs, 41 DLBCLs, and 5 with the pathological
diagnosis of BCL-U (Figure 3B). Among the non-BLs were
one genetic single-hit lymphoma [genetic SHL, with iso-
lated MYC translocation (tDLBCL1)] and eight genetic
DHLs, all with MYC translocations. Seven DHLs had
coexistent BCL2 translocations, and one DHL had a coex-
istent BCL6 translocation, tDHL1-8 (Figure 3B).
The diagnostic classiﬁer successfully segregated all patho-
logical BLs from all DLBCLs (Figure 3B and Table 1). Of 50,
46 (92%) of BLs and DLBCLs were classiﬁed with high
conﬁdence. Two BLs and two DLBCLs had intermediate
diagnostic scores, but among these, the diagnostic scores for
the BL were >0.5 and for the DLBCL, 0.5. The DLBCL
with the highest diagnostic score (case tDLBCL1,
score Z 0.5) was the genetic SHL. The diagnostic classiﬁer
demonstrated a sensitivity of 1.0 (95% CI, 0.59e1.0) and a
speciﬁcity of 1.0 (95% CI, 0.91e1.0) in the test set, for all
tumors classiﬁed asmBL ormDLBCL (Table 1).We conclude
that in our test cohort, a 21-gene classiﬁer can be used to
distinguish most (92%) of pathological BLs from DLBCLs.
Molecular classiﬁcation segregated subsets of non-BLs
with the pathological diagnosis of BCL-U and/or genetic
evidence for MYC rearrangements into all three diagnostic
categories (Figure 3B). Three BCL-U/DHLs (tDHL1,
tDHL2, and tDHL3) had high diagnostic scores (0.90, 0.85,
and 0.77, respectively) and were classiﬁed as mBL. One
DLBCL/SHL (tDLBCL1) and one BCL-U/DHL (tDHL4)
had lower diagnostic scores (0.50 and 0.31, respectively)
and were classiﬁed as molecularly intermediate. Finally, onegnostic classiﬁer for the training cohort: Burkitt lymphoma (BL) and diffuse
est cohort: BL, B-cell lymphoma unclassiﬁable (BCL-U), and DLBCL cases
lar diagnosis (diagnostic scores of 0.25 to 0.75 categorized as molecularly
ive expression of the indicated transcripts (heat map), including the relative
angement status. The cases of genetic double hit lymphomas are numbered,
le (BCL6-). The single-hit DLBCL, with MYC-rearrangement only, is indicated
jmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 Performance Statistics of Molecular Classiﬁers
Variable
Diagnostic classiﬁer* MYC activity classiﬁery
Training Test Training, all Training, non-BL Test, all Test, non-BL Outcome series
Cases
classiﬁed (%)
85 92 100 100 100 100 100
Accuracy 1 1 0.93 0.90 0.80 0.80 0.87
Sensitivity
(95% CI)
1 (0.66e1.0) 1 (0.59e1.0) 0.92 (0.73e0.99) 0.85 (0.55e0.98) 0.77 (0.55e0.92) 0.69 (0.41e0.89) 0.75 (0.35e0.96)
Speciﬁcity
(95% CI)
1 (0.87e1.0) 1 (0.91e1.0) 0.94 (0.70e0.99) 0.94 (0.70e0.99) 0.83 (0.64e0.94) 0.86 (0.67e0.96) 0.90 (0.73e0.98)
PPV 1 1 0.96 0.92 0.77 0.73 0.67
NPV 1 1 0.88 0.88 0.83 0.83 0.93
*Only cases classiﬁed with high conﬁdence (as mBL or mDLBCL) were included. The sensitivity refers to the ability of the test to identify pathological BL as
mBL.
yOnly cases with matched MYC IHC and MYC activity scores were included. The sensitivity refers to the ability of the test to identify tumors with high MYC IHC
expression (>50%) as having MYC activity score >0.5.
NPV, negative predictive value; PPV, positive predictive value.
Proﬁling of Aggressive B-Cell LymphomasBCL-U/DHL (tDHL5) and three DLBCL/DHLs (tDHL6,
tDHL7, and tDHL8) had low diagnostic scores (0.12, 0.05,
0.02, and 0.015, respectively) and were classiﬁed as
mDLBCL. We conclude that the diagnostic molecular
classiﬁer reveals molecular heterogeneity among BCL-Us
and DLBCLs with MYC translocations.
Molecular and Histopathological Features of
BCL-U/DHL
We next examined the molecular signatures and histopath-
ological features of the BCL-Us and DLBCLs with MYC
translocations in more detail (Figure 4). BCL-U/DHLs
classiﬁed as mBL expressed both TCF3-associated tran-
scripts and MYC-associated transcripts at levels that were
comparable to BL (Figure 4A). DLBCL/DHLs classiﬁed
as mDLBCL expressed TCF3-associated transcripts at low
levels and MYC-associated transcripts at intermediate
levels, which were comparable to many DLBCLs lacking
a MYC translocation (Figure 4A). Additional transcripts
(BCL2, CD44, NFKB1, and BCL2A1), differentially
expressed between BL and DLBCL, also showed differ-
ential expression among the DHLs, and with the TCF3
and MYC signatures, resulted in the ﬁnal classiﬁcation
indicated in Figure 3B.
Further review of the histopathological features of the
DHLs revealed distinct features between those that classify
with high conﬁdence as mBL and those that classify with
high conﬁdence as mDLBCL (Figure 4B). Cases classiﬁed as
mBL were composed of sheets of tightly packed, interme-
diate- to large-sized cells with homogeneous, round nuclei
and scant cytoplasm, which resembles the morphological
features of classic BL. In contrast, cases classiﬁed as
mDLBCL were composed of large-sized lymphoid cells with
marked pleomorphism and nuclear irregularity typical of
DLBCL. We conclude that the ﬁnal molecular classiﬁcations
of DHLs are supported by multiple molecular signatures, and
correlate with distinct histopathological characteristics.The Journal of Molecular Diagnostics - jmd.amjpathol.orgPerformance of the MYC Activity Classiﬁer on the
Training and Test Sets
The MYC activity classiﬁer was tested in the training
cohort by LOO-CV. BLs were not used to build the
classiﬁer, but as expected, had high MYC activity scores
(Figure 5A). In addition, all non-BLs with MYC trans-
location had MYC activity scores >0.5. The sensitivity
and speciﬁcity of the molecular classiﬁer for identifying
MYC IHC-High among all cases in the training set were
0.92 (95% CI, 0.73e0.997) and 0.94 (95% CI,
0.70e0.99), respectively (Table 1). Overall, the correla-
tion between the optimized, molecular MYC activity
score and MYC IHC score among non-BLs in the training
set was high (Spearman r Z 0.80, P < 0.0001, 95% CI,
0.6e0.9) (Figure 5A).
We next applied the MYC activity classiﬁer to expression
data from the test set. Again, BL cases showed high MYC
activity scores (Figure 5B). The sensitivity and speciﬁcity of
the molecular classiﬁer identifying MYC IHC-High among
all cases were 0.77 (95% CI, 0.55e0.92) and 0.83 (95% CI,
0.64e0.94), respectively (Table 1). The correlation between
the molecularMYC score and theMYC IHC score for the test
set (non-BLs) was lower than for the LOO-CV of the training
set, but with overlapping CIs, thus preventing deﬁnitive
comparison (Spearman r Z 0.66, P < 0.0001, 95% CI,
0.44e0.8).
Non-BLs with aMYC translocation were expected to have
up-regulated MYC activity, and for ﬁve of nine cases,
tDHL1-4 and tDHL6, the MYC activity scores were high and
comparable to those seen for BL (range, 0.98 to 1.00). There
was a range of values among the remaining cases. For
tDLBCL1 (genetic SHL) and tDHL5, the MYC activity
scores were 0.63 and 0.60; and for tDHL7 and tDHL8, the
scores were lower, at 0.26 and 0.18, respectively. Non-BLs
with MYC translocations and high MYC activity scores had
a pathological diagnosis of BCL-U, whereas those with other
MYC activity scores had a pathological diagnosis of25
Figure 4 A: Scatterplot shows the mean TCF3 signature (seven genes, x axis) and mean MYC signature (10 genes, y axis) for each tumor from the test
cohort. The mean values for each signature are derived from transcript counts from these genes, as originally used in the diagnostic classiﬁer. Colors indicate
the pathological/genetic diagnoses [black for Burkitt lymphoma (BL), gray for diffuse large B-cell lymphoma (DLBCL), and yellow for genetic double hit
lymphomas (DHLs)]. Shapes indicate the molecular classiﬁcation assigned by the diagnostic classiﬁer [triangle for molecular (m)BL, circle for molecular DLBCL
(mDLBCL), and square for molecularly intermediate]. B: Histomorphological features of lymphomas with a MYC rearrangement and either a BCL2- or BCL6-
rearrangement (genetic DHL). H&E-stained sections of DHL classiﬁed as mBL and mDLBCL. Unique identiﬁers and details of relevant translocations are shown.
The tumors classiﬁed as mDLBCL have insets highlighting nuclear morphological characteristics. Original magniﬁcation, 1000 (main images and insets).
Carey et alDLBCL. We conclude that the MYC activity classiﬁer cap-
tures a spectrum of MYC biological activity in BCL-U and
DLBCL that shows good correlation with MYC IHC and
reveals heterogeneity in MYC biological activity among
non-BL with MYC translocations.Figure 5 A: Leave-one-out cross-validation of the ﬁnal proﬁling panel and
diffuse large B-cell lymphoma (DLBCL) are segregated by pathological diagnosis
transcripts (heat map), including the relative contribution of each to the classiﬁe
High >50), and MYC rearrangement status. Inset: The correlation between MYC
0.6e0.9). B: Results of the ﬁnal proﬁling panel and MYC activity classiﬁer for th
segregated by pathological diagnosis, MYC activity score (line graph), the relativ
contribution of each to the classiﬁer (horizontal, shaded bar graphs), MYC IHC cl
Genetic double hit lymphomas are numbered and additional gene rearrangement
DLBCL, with MYC-rearrangement only, is indicated by an asterisk. Inset: The
(Spearman r Z 0.66; 95% CI, 0.44e0.8). Max, maximum; min, minimum.
26Clinical Signiﬁcance of the MYC Activity Score in DLBCL
The MYC activity classiﬁer was constructed to categorize
aggressive B-cell lymphomas, according to MYC biological
activity, rather than to predict clinical outcome. The MYCMYC activity classiﬁer for the training cohort. Burkitt lymphoma (BL) and
, MYC activity score (line graph), the relative expression of the indicated
r (horizontal, shaded bar graphs), MYC IHC class (MYC IHC-Low 50%, IHC-
IHC and MYC activity score for DLBCL only (Spearman r Z 0.80; 95% CI,
e test cohort, BL, DLBCL, and B-cell lymphoma unclassiﬁable (BCL-U), are
e expression of the indicated transcripts (heat map), including the relative
ass (MYC IHC-Low 50%, IHC-High >50%), and MYC rearrangement status.
s are indicated by arrowheads (BCL2-) or a circle (BCL6-). The single-hit
correlation between MYC IHC and MYC activity score for non-BL only
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MYC IHC scores in the training and test sets. Therefore, we
wanted to determine whether the results of the MYC classi-
ﬁer were sufﬁcient to predict clinical outcome in a series for
which MYC IHC has prognostic value.15 DLBCLs with
MYC activity scores in excess of the optimized classiﬁer cut
point of 0.5 identiﬁed a patient population with inferior
overall survival that was highly signiﬁcant (nominal
PZ 0.0009, log-rank test; hazard ratioZ 6.73) (Figure 6B).
The correlation between MYC activity and MYC IHC scores
was similar to the training and test sets, as expected
(rZ 0.64, P < 0.0001, 95% CI, 0.4e0.8) (Figure 6A). We
conclude that the MYC activity classiﬁer, built on MYC IHC
data (Supplemental Figure S3), is capable of dividing patients
into high- and low-risk categories.
Discussion
The World Health Organization currently considers histo-
morphological, immunophenotypic, and genomic data to
categorize aggressive B-cell lymphomas.1 However, the
interpretation of histomorphological and IHC data remains
subjective and requires expert review. Molecular proﬁling
has the potential to aid diagnostic categorization by providing
objective data from normalized gene expression signatures,
but until recently, the degradation of RNA due to formalin
compromised the ability to use ﬁxed biopsy specimens.23e26
We have described a framework for the molecular classiﬁ-
cation of MYC-driven B-cell lymphomas using targeted
expression proﬁling of RNA isolated from FFPE tissue. TheFigure 6 Results of the MYC classiﬁer and overall survival among patients
with primary diffuse large B-cell lymphoma treated with R-CHOP (rituximab,
cyclophosphamide, doxorubicin, vincristine, prednisone)ebased chemo-
therapy. A: The correlation between MYC score and MYC IHC for the outcome
series (Spearman rZ 0.64; 95% CI, 0.4e0.8). B: Kaplan-Meier curve shows OS
for the outcome series with a MYC score>0.5 (red line) and a MYC score<0.5
(black line).
The Journal of Molecular Diagnostics - jmd.amjpathol.orgapproach described has several features that make it appealing.
First, the assay requires only small amounts of FFPE tissue.We
and others ﬁnd that RNA isolated from the equivalent of 2 to
6 FFPE tissue sections (5 mm thick) is sufﬁcient for anal-
ysis.24 Second, the assay is robust. We successfully proﬁled 96
FFPE tumor biopsy samples ranging from 0.5 to 13 years old,
with only an additional 5 (5%) failing analytical quality control,
and repeat testing of the same samples yielding nearly identical
results. Third, the step-wise application of the diagnostic and
MYC activity classiﬁers mimics the diagnostic approach used
to evaluate aggressive B-cell lymphomas in clinical practice.
Fourth, the molecular scores provide quantitative outputs that
can be interpreted objectively. Thus, the assessment of deﬁned
molecular signatures from FFPE tissue, by using the methods
described herein, has the potential to provide important addi-
tional biological information alongside traditional diagnostic
techniques, to facilitate lymphoma classiﬁcation.
We framed our deﬁnition of BL in terms of high MYC and
TCF3 transcriptional activity, because these are knownmajor
determinants of tumor behavior.4e6 DLBCL was deﬁned by
variable MYC activity, low TCF3 activity, and high BCL2
and targets of NF-kB.12 This limited signature was sufﬁcient
to categorize >90% of BL and DLBCL in the test set with
high conﬁdence and with perfect accuracy (Table 1). The
results are comparable to those reported in a prior exploratory
study comparing categorization of BL and non-BL using
targeted GEP against a gold standard global GEP,25 and
validate a molecular diagnostic classiﬁcation for cases of
well-deﬁned BL and DLBCL.
BCL-Us are intermediate tumors that share features with BL
and DLBCL, according to traditional diagnostic evaluation,
but intermediate tumors are also identiﬁed by molecular ana-
lyses.1,12,13 Histomorphologically intermediate and molecu-
larly intermediate are nonsynonymous terms and will
categorize mature, aggressive B-cell lymphomas in different
ways.42 For example, in our test cohort, three BCL-Us were
classiﬁed as mBL. This must be considered inaccurate in the
context of World Health Organization classiﬁcation but is
consistent with prior molecular characterization of B-cell
lymphomas in which most atypical BLs and a proportion of
unclassiﬁable aggressive B-cell lymphomas were classiﬁed as
mBL.13 Similarly, few BLs, BCL-Us, and DLBCLs in our
series had diagnostic molecular scores intermediate between
mBL and mDLBCL. This result is also consistent with prior
analyses in which subsets of atypical BL, unclassiﬁable
aggressive B-cell lymphoma, and DLBCL were classiﬁed as
molecularly intermediate.13 These results support the concept
that BCL-U is not a discrete diagnostic category, but includes
tumors with molecular proﬁles of mBL, mDLBCL, and
intermediate between mBL and mDLBCL.
Non-BL with MYC rearrangement is also a heterogeneous
group that includes tumors with the pathological diagnoses of
BCL-U and DLBCL by World Health Organization
criteria.1,42e46 We found DHLs that classiﬁed as mBL,
molecularly intermediate, and mDLBCL. This result also has
precedence. A comprehensive GEP analysis of aggressive27
Carey et alB-cell lymphomas highlighted groups of DHLs that classiﬁed
as mBL and MYC-rearranged DLBCLs that classiﬁed
as mDLBCL.12
Our results were further supported by the examination of
the molecular subsignatures and the histomorphological
features of the DHLs. We found that a subset of DHLs have
a TCF3 signature that is comparable to or exceeds that of
BL. This result was surprising, given recent reports that the
TCF3 signature is speciﬁc for BL,5,6 although a recent study
found that ID3 mutations can occur in DHL.45 It will be of
interest to correlate TCF3/ID3 mutation status with molec-
ular diagnosis in future studies.
DHLs that classiﬁed as mBL were histomorphologically
typical of BL and cases that classiﬁed as mDLBCL were
histomorphologically typical of DLBCL. Morphological
heterogeneity among DHLs is recognized and may have
clinical signiﬁcance.47 It will be important to determine, by
using larger cohorts, whether the molecular classiﬁer reliably
identiﬁes subsets of DHL with distinct histomorphological
characteristics, and to relate these data to clinical outcomes.
The prognostic role of MYC in DLBCL is well established,
especially in the context of BCL2 expression, and an assess-
ment of MYC activity has been proposed to be an important
part of the diagnostic workup.14e16,19e21,48 MYC IHC is a
single biomarker that serves as a surrogate for MYC activity.
The threshold forMYC IHC that separates low- from high-risk
disease varies between studies, from 10% to 50%, with most
suggesting 40%.14e16,19e21,49 However, IHC is difﬁcult to
standardize between centers, even if an automated platform is
used.22 Therefore, we anticipated that the MYC activity scores
would show good, but not perfect, correlation with MYC IHC
scores, which we observed. There are several pre-analytical
and analytical variables that we must consider when review-
ing MYC IHC data, such as time to tissue ﬁxation and intra-
observer and interobserver variability in assessment. A
potential advantage of expression proﬁling is that the analysis
of many gene transcripts provides redundancy to the assay and
captures a transcriptional signature of MYC activity that IHC
for MYC alone cannot offer. However, comparing between a
single data point (MYC protein expression by IHC) and the
combination of a broad set of data (MYC activity score) is also
likely to contribute to the observed imperfect correlation be-
tween the two methods of assessment. It is also possible that
additional MYC targets, not included in our ﬁnal proﬁling
panel, would improve the validity of the MYC activity score.
The MYC activity classiﬁer was trained using the GEPs
of DLBCLs alone, excluding BLs. Its subsequent applica-
tion to BLs in the training and test sets revealed high MYC
activity scores for all cases, which supports the validity of
the classiﬁer. Moreover, ﬁve of six non-BLs with the
highest MYC activity scores in the test set had MYC
translocations. Yet, we also observed tumors with MYC
translocations and intermediate/low scores, indicating vari-
able MYC activity among SHLs and DHLs.13,44
To evaluate the clinical relevance of these data, we correlated
the MYC activity scores to clinical outcome in a small series of28R-CHOPetreated patients with primary, de novo DLBCL.
Segregating tumors into those with high (>0.5) and low (<0.5)
MYC activity scores identiﬁed patient populations that differed
signiﬁcantly with respect to overall survival (nominal
PZ 0.0009). The results provide evidence that the MYC ac-
tivity score, while showing imperfect correlation with IHC and
genetics, captures a biological signature of clinical signiﬁcance.
The limited number of primary DLBCLs with documented
treatment and outcome required that we include cases from the
training and test sets; therefore, a more formal validation of the
MYC classiﬁer using an independent case series is needed.
Ideally, such a study would compare the interinstitutional
reproducibility and the prognostic value of the MYC classiﬁer
with MYC IHC in a large, multi-institutional cohort.
In summary, we have developed a quantitative method for
classifying and stratifying aggressive B-cell lymphomas that is
applicable to FFPE tissue samples. The molecular classiﬁers
are robust, but likely to improve with further testing and with
the inclusion of additional, select gene signatures.24 In addition
to distinguishing BL from DLBCL, the diagnostic classiﬁer
provides unique data regarding the further classiﬁcation of
BCL-Us and DHLs that inform the standard diagnostic
methods and warrant further investigation. This platform will
allow for the standardized analysis of an expanded cohort of
BCL-Us and DHLs, from which correlations between GEP
and traditional pathological, genetics, and somatic mutational
analysis can be further examined. The MYC activity classiﬁer
captures a key biological and prognostic hallmark of DLBCL
and also has the potential to standardize assessment across
institutions. The ability of this classiﬁer to predict outcome
requires further validation, initially in a large independent
cohort in which MYC IHC expression is known to be pre-
dictive of outcome, and then in the context of a clinical trial.
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